Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

AQST stock hub

Aquestive Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AQSTis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

536.9M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

AQST

In the news

Latest news · AQST

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROICn/a

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AQST market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

205

Groups with data

Currency

USD

Showing 205 of 205 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001398733
Company name	Aquestive Therapeutics, Inc.
Country	United States
Country code	US
Cusip	03843E104
Employees	147
Employees Change	5%
Employees Change Percent	3.52
Enterprise value	$458.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2018-07-25
Isin	US03843E1047
Last refreshed	2026-05-10
Market cap	$536.9M
Market cap category	Small-Cap
Price	$4.32
Price currency	USD
Rev Per Employee	303,027.21x
Sector	Healthcare
Sic	2834
Symbol	AQST
Website	https://www.aquestive.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-15.6%
EV Sales Forward	9.35x
EV/Sales	10.29x
FCF yield	-9.87%
P/S ratio	12.05x
PS Forward	10.95x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-159.5%
EBITDA Margin	-158.22%
Gross margin	58.35%
Gross Profit	$26M
Gross Profit Growth	-34.52%
Gross Profit Growth Q	-2.29%
Gross Profit Growth3 Y	-2.79%
Gross Profit Growth5 Y	-4.6%
Net Income	$-83.8M
Net Income Growth Years	0%
Pretax Margin	-188.09%
Profit Margin	-188.09%
Profit Per Employee	$-569,959
ROA	-33.92
Roa5y	-30.7
ROCE	-62.98

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	58.29%
Cagr3y	28.41%
Cagr5y	4.78%
EPS Growth Years	0
Revenue Growth	-22.61x
Revenue Growth Q	9.67x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	-2.24x
Revenue Growth5 Y	-0.58x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.34
Assets	$160.4M
Cash	$121.2M
Current Assets	$149.3M
Current Liabilities	$47.6M
Debt	$42.5M
Equity	$-33.7M
Interest Coverage	-4.16
Liabilities	$194.1M
Long Term Assets	$11.2M
Long Term Liabilities	$146.5M
Net Cash	$78.7M
Net Cash By Market Cap	$14.66
Net Cash Growth	134.6%
Tangible Book Value	$-33.7M
Tangible Book Value Per Share	$-0.28
WACC	13.89

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.14
Inventory Turnover	3.04
Net Working Capital	$-8.9M
Quick ratio	2.92
Working Capital	$101.7M
Working Capital Turnover	$0.52

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-23.29%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	58.24%
200-day SMA	4.86
3Y total return	111.77%
50-day SMA	4.15
50-day SMA vs 200-day SMA	50under200
5Y total return	26.32%
All Time High	20.7
All Time High Change	-79.13%
All Time High Date	2018-09-13
All Time Low	0.62
All Time Low Change	599.03%
All Time Low Date	2022-07-01
ATR	0.15
Beta	1.5
Beta1y	0.22
Beta2y	0.87
Ch YTD	-33.13
High	4.36
High52	7.55
High52 Date	2025-10-20
High52ch	-42.78%
Low	4.25
Low52	2.12
Low52 Date	2025-05-13
Low52ch	103.77%
Ma50ch	4.15%
Premarket Change Percent	-0.24
Premarket Price	$4.22
Premarket Volume	961
Price vs 200-day SMA	-11.15%
RSI	59.5
RSI Monthly	51.69
RSI Weekly	48.96
Sharpe ratio	0.92x
Sortino ratio	1.52
Total Return	-23.29%
Tr YTD	-33.13
Tr1m	4.6%
Tr1w	2.86%
Tr3m	5.11%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	3
Analyst Price Target Top	$9
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.13
Earnings Revenue Estimate	10,884,800x
Earnings Revenue Estimate Growth	24.83x
Operating Income	$-71.1M
Operating margin	-159.5
Price target	$9
Price Target Change	$108
Price Target Change Top	$108

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	114,650,484%
Float Percent	92.25%
Net Borrowing	-26,000
Shares Insiders	2.72%
Shares Institutions	54.99%
Shares Out	124,284,542
Shares Qo Q	10.29%
Shares Yo Y	23.29%
Short Float	13.54%
Short Ratio	11
Short Shares	12.49

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-60.6M
Average Volume	1,230,104.2x
Bv Per Share	-0.28
CAPEX	$-562,000
Ch1m	4.6
Ch1w	2.86
Ch1y	58.24
Ch3m	5.11
Ch3y	111.8
Ch5y	26.32
Ch6m	-28.48
Change	2.13%
Change From Open	1.65
Close	4.23
Days Gap	0.47
Depreciation Amortization	574,000
Dollar Volume	8,177,539.7
Earnings Date	2026-05-13
Earnings Time	amc
EBIT	$-71.1M
EBITDA	$-70.5M
EPS	$-0.78
F Score	2
FCF	$-53M
FCF EV Yield	-11.57x
FCF Per Share	$-0.43
Financing CF	102,617,000
Fiscal Year End	December
Founded	2,004
Investing CF	-562,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-04
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-04
Ma150	4.98
Ma150ch	-13.31%
Ma20	4.19
Ma20ch	3.15%
Net CF	49,623,000
Next Earnings Date	2026-05-13
Open	4.25
Optionable	Yes
Position In Range	65.22
Post Close	4.32
Postmarket Change Percent	-0.69
Postmarket Price	$4.29
Ppne	8,514,000
Pre Close	4.23
Price Date	2026-05-08
Relative Volume	1.54x
Revenue	44,545,000x
SBC By Revenue	17.12x
Share Based Comp	7,624,000
Tr6m	-28.48%
Us State	New Jersey
Volume	1,892,949
Z Score	-2.92

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AQST pay a dividend?

Capital-return profile for this ticker.

Performance

AQST stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AQST?

Insider, institutional, and short-interest positioning.

Institutional ownership

+55.0%

Float: +92.2% of shares outstanding

Insider ownership

+2.7%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AQST momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

59.5

Neutral momentum band

Price vs 200-day MA

-11.1%

50/200-day relationship not available

Beta (5Y)

1.50

More volatile than the market

Sharpe ratio

0.92

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AQST

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AQST stock rating?

Aquestive Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AQST analysis?

The full report lives at /stocks/AQST/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AQST?

The latest report frames AQST around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AQST page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.